Accuray (NASDAQ:ARAY) Announces Earnings Results

Accuray (NASDAQ:ARAY) posted its earnings results on Wednesday. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04), Zacks reports. The firm had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative return on equity of 33.65% and a negative net margin of 3.48%. During the same quarter in the prior year, the business posted ($0.03) earnings per share. Accuray updated its FY 2025 guidance to EPS.

Accuray Price Performance

Shares of ARAY traded down $0.01 during trading hours on Friday, reaching $2.08. 180,514 shares of the company’s stock traded hands, compared to its average volume of 660,884. The company has a current ratio of 1.66, a quick ratio of 0.95 and a debt-to-equity ratio of 3.65. The firm’s 50 day simple moving average is $1.89 and its 200-day simple moving average is $1.84. The stock has a market cap of $208.56 million, a PE ratio of -13.06 and a beta of 1.40. Accuray has a 12 month low of $1.40 and a 12 month high of $3.05.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Accuray from a “hold” rating to a “buy” rating in a report on Thursday.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.